Lastly, depletion of myeloid IKKβ resulted in enhanced late long-term potentiation in EAE, suggesting that brain cognitive abilities may be also affected by the use of approved treatments against NF-κB activity in MS, which needs to be taken into consideration. Here, NFKB1 is linked to myeloid sarcoma.